Cargando…

Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis

PURPOSE: Symptom control in the long-term with less side effects is important in perennial allergic conjunctivitis, since would improve quality of life. This study aimed to assess the clinical efficacies of topical cyclosporin A and subcutaneous allergen immunotherapy (SCIT) in terms of sign control...

Descripción completa

Detalles Bibliográficos
Autores principales: Dogan, Ceylan Uslu, Tuzer, Can, Turker, Ibrahim Cagri, Alkan, Abdurrahman Alpaslan, Culha, Damla, Demir, Semra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747541/
https://www.ncbi.nlm.nih.gov/pubmed/36513916
http://dx.doi.org/10.1007/s10792-022-02612-y
_version_ 1784849623011033088
author Dogan, Ceylan Uslu
Tuzer, Can
Turker, Ibrahim Cagri
Alkan, Abdurrahman Alpaslan
Culha, Damla
Demir, Semra
author_facet Dogan, Ceylan Uslu
Tuzer, Can
Turker, Ibrahim Cagri
Alkan, Abdurrahman Alpaslan
Culha, Damla
Demir, Semra
author_sort Dogan, Ceylan Uslu
collection PubMed
description PURPOSE: Symptom control in the long-term with less side effects is important in perennial allergic conjunctivitis, since would improve quality of life. This study aimed to assess the clinical efficacies of topical cyclosporin A and subcutaneous allergen immunotherapy (SCIT) in terms of sign control in perennial allergic conjunctivitis. METHODS: This retrospective study included 20 adult patients with perennial allergic conjunctivitis and confirmed sensitization to house dust mites with skin prick test. Patients were assigned to either topical cyclosporine A treatment or SCIT. The participants were followed for 6 months, and signs scores were recorded at 1, 3 and 6 months. RESULTS: Overall, both cyclosporine and immunotherapy groups showed significant improvements in papillary reaction (p = 0.011 and 0.003, respectively), limbal involvement (p = 0.031 and 0.001), and conjunctival hyperemia (p = 0.001 and p < 0.001) scores during the 6-month follow-up. However, only cyclosporine group showed a significant improvement in corneal involvement scores (p = 0.015) during the study period. When scores at different time points were compared, significant improvement in conjunctival hyperemia was evident at 6 months in both groups when compared to baseline (cyclosporine group, 0.7 ± 0.68 vs. 2.4 ± 0.84, 70.8% decrease, p = 0.01; immunotherapy group, 0.3 ± 0.48 vs. 2.3 ± 0.95, 87.0% decrease, p = 0.004), whereas for limbal involvement such an improvement was only evident in the immunotherapy group (0.1 ± 0.32 vs. 1.3 ± 0.95, 92.3% decrease, p = 0.01). CONCLUSIONS: Allergen immunotherapy and cyclosporin A treatment may provide effective sign relief in perennial allergic conjunctivitis. It may represent an encouraging treatment option particularly for cases with perennial allergic conjunctivitis refractive to other treatments and positive skin prick test to a specific allergen (house dust in the present study). Long-term relief by SCIT would reduce the side effects of polypharmacotherapy. Larger studies with longer follow-up are warranted to confirm our findings.
format Online
Article
Text
id pubmed-9747541
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-97475412022-12-14 Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis Dogan, Ceylan Uslu Tuzer, Can Turker, Ibrahim Cagri Alkan, Abdurrahman Alpaslan Culha, Damla Demir, Semra Int Ophthalmol Original Paper PURPOSE: Symptom control in the long-term with less side effects is important in perennial allergic conjunctivitis, since would improve quality of life. This study aimed to assess the clinical efficacies of topical cyclosporin A and subcutaneous allergen immunotherapy (SCIT) in terms of sign control in perennial allergic conjunctivitis. METHODS: This retrospective study included 20 adult patients with perennial allergic conjunctivitis and confirmed sensitization to house dust mites with skin prick test. Patients were assigned to either topical cyclosporine A treatment or SCIT. The participants were followed for 6 months, and signs scores were recorded at 1, 3 and 6 months. RESULTS: Overall, both cyclosporine and immunotherapy groups showed significant improvements in papillary reaction (p = 0.011 and 0.003, respectively), limbal involvement (p = 0.031 and 0.001), and conjunctival hyperemia (p = 0.001 and p < 0.001) scores during the 6-month follow-up. However, only cyclosporine group showed a significant improvement in corneal involvement scores (p = 0.015) during the study period. When scores at different time points were compared, significant improvement in conjunctival hyperemia was evident at 6 months in both groups when compared to baseline (cyclosporine group, 0.7 ± 0.68 vs. 2.4 ± 0.84, 70.8% decrease, p = 0.01; immunotherapy group, 0.3 ± 0.48 vs. 2.3 ± 0.95, 87.0% decrease, p = 0.004), whereas for limbal involvement such an improvement was only evident in the immunotherapy group (0.1 ± 0.32 vs. 1.3 ± 0.95, 92.3% decrease, p = 0.01). CONCLUSIONS: Allergen immunotherapy and cyclosporin A treatment may provide effective sign relief in perennial allergic conjunctivitis. It may represent an encouraging treatment option particularly for cases with perennial allergic conjunctivitis refractive to other treatments and positive skin prick test to a specific allergen (house dust in the present study). Long-term relief by SCIT would reduce the side effects of polypharmacotherapy. Larger studies with longer follow-up are warranted to confirm our findings. Springer Netherlands 2022-12-14 /pmc/articles/PMC9747541/ /pubmed/36513916 http://dx.doi.org/10.1007/s10792-022-02612-y Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Dogan, Ceylan Uslu
Tuzer, Can
Turker, Ibrahim Cagri
Alkan, Abdurrahman Alpaslan
Culha, Damla
Demir, Semra
Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title_full Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title_fullStr Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title_full_unstemmed Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title_short Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
title_sort topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747541/
https://www.ncbi.nlm.nih.gov/pubmed/36513916
http://dx.doi.org/10.1007/s10792-022-02612-y
work_keys_str_mv AT doganceylanuslu topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis
AT tuzercan topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis
AT turkeribrahimcagri topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis
AT alkanabdurrahmanalpaslan topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis
AT culhadamla topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis
AT demirsemra topicalcyclosporineversusallergenspecificimmunotherapyinperennialallergicconjunctivitis